III. Parkinson Disease.

Slides:



Advertisements
Similar presentations
Sporadic AD familial AD etiology environmental factors, genetic predisposition etiology oligomerization of A 42 and initial (diffuse) A 42 deposits subtle.
Advertisements

Parkinson’s disease: February 19th BIOS E108 Parkin and PINK1
Cortically OriginatedMovement Cortically Originated Movement I. Motor Tract (corticospinal tractus) Extrapyramidal System (basal ganglia) Cerebellum Praxis.
Parkinson’s Disease Shirley H. Wray, M.D., Ph.D., Professor of Neurology, Harvard Medical School Director, Unit for Neurovisual Disorders Massachusetts.
Movement part 2. Cerebellum and Brainstem KW p. 363.
PHL 437/Pharmacogenomics Fourth Lecture (Parkinson’s disease) By Abdelkader Ashour, Ph.D. Phone:
Parkinson’s Disease Pathology 430/826 The Molecular Basis of Disease Neurological Genetics 9 th March 2015 Dr. John Rossiter
Lewy Bodies in PD. Lewy Body Inclusions and the effect of coffee and decaffeinated extracts on Drosophila neuronal cultures.
Module 7.3 Movement Disorders. Parkinson’s Disease A neurological disorder characterized by muscle tremors, rigidity, slow movements and difficulty initiating.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
931-4 Convergence Insufficiency. History A 73-year old man with known PD for 10 years, complained of horizontal double vision for 18 months. He could.
Degenerative brain disease The term “Degenerative”: – an underlying cellular degeneration of neurons in the brain Cause symptoms that depend on the pattern.
Introduction to Degenerative Brain Diseases
Brain Dysfunction Department of pathophysiology, Tongji medical college, HUST.
Diseases that Result from Abnormal Mitochondrial Function Lu Qiping April 15, 2011.
Parkinson’s Disease superKAT :).
PhD MD MBBS Faculty of Medicine Al Maarefa Colleges of Science & Technology Faculty of Medicine Al Maarefa Colleges of Science & Technology Lecture – 9:
PATHOLOGIC AGGREGATION OF THE BRAIN PROTEIN  -SYNUCLEIN CAUSES CELL DEATH IN PARKINSON AND ALZHEIMER DISEASE, Wenbo Zhou, PhD and Curt R. Freed, MD Division.
BASAL GANGLIA Basal ganglia are subcorticle nuclei of grey matter located in the interior part of cerebrum near about base 3.
Molecular Biology and Genetics of Amyotrophic Lateral Sclerosis Michael Sidel February 13, 2008.
Mitochondria in the etiology and pathogenesis of Parkinson's disease
Mounting Evidence that Endocytosis Regulates  -Synuclein Degradation Jaime Pérez Pineda Advanced Cell Biology Fall 2009.
A 53-year-old male with clumsiness Leonidas Arvanitis, M.D. Neuropathology Fellow, PGY-6.
Mitochondrial function in Cell death in PD. Pathology Loss of SN pigmented dopamine neurons Lewy bodies Lewy neurites-multiple brain regions Lewy bodies.
Central nervous system block practical revision.
The organization of the nervous system. Structure of the human cerebral cortex.
Α-synuclein transgenic mouse models of Parkinson’s disease Michelle Maurer December 2015.
Pathologic features of AD. Pathologic changes (specifically plaques, tangles, and the associated neuronal loss and glial reaction) a. Are evident first.
PARKINSON’S DISEASE Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine.
Pathogenesis and pathology of parkinsonism
Direct motor pathway Corticospinal pathway. Motor Units – Large Versus Small Text Fig
Direct motor pathway Corticospinal pathway.
Sapana Shinde, Aaron Ripley, Dr. Sok Kean Khoo MicroRNA expression studies in rotenone- induced cellular model for Parkinson’s disease Department of Cell.
DISORDERS OF THE MOTOR SYSTEM
Parkinson’s Disease.
The ageing brain Volume reduction: begins around 50 with a loss of brain weight of around 2-3% per decade Changes in nerve cell numbers and size - various.
Idiopathic Parkinson disease
Module 7.3 Movement Disorders
Degenerative brain disease
Parkinson's disease KRZYSZTOF NICPOŃ.
Nitric Oxide (NO) and How it Regulates Motor Function
BASAL GANGLIA Prof.Musaad Alfayez.
CNS Iron in Parkinson’s Disease
Treatment of Parkinson’s disease
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Parkinson’s disease.
Parkinson's disease Parkinson's disease (PD) is the second-most common
Justin Hayase MSTAR Presentation Guo Lab July 23,2009
Long Term Effects of Concussions
Alpha-synuclein in Parkinson's disease
Zhejiang University Ling Shucai
Parkinson’s Common neurodegenerative disorder ~10-20/1000
Introduction to movement disorders and parkinsonism
Understanding the structure of a protein involved in Parkinson’s disease -My research proposal was “Relating the structure of aggregated alpha synuclein.
Basal ganglia movement modulation
Basal ganglia function
Parkinson’s Disease By: Megan Muth Period 3.
Justin Hayase MSTAR Presentation Guo Lab July 23,2009
Parkinson's Disease Neuron
Basal ganglia It is a collection of grey matter deeply in each
NEURODEGENERATIVE DISEASES
Neurodegenerative diseases
Basal Ganglia April 28, 2019 basal ganglia.
BASAL GANGLIA Prof.Musaad Alfayez.
FUNCTIONS OF THE BASAL NUCLEI FUNCTIONS OF THE BASAL NUCLEI assist in the regulation of voluntary movement & the learning of motor skills initiate movement.
Genetic Animal Models of Parkinson's Disease
Introduction to degenerative brain disease
PD-associated gene products and their prospective sites of cellular function PD is hypothesized to be a consequence of the dysfunction of intersecting.
BASAL NUCLEI. BASAL NUCLEI Basal Ganglia Functions Compare proprioceptive information and movement commands. Sequence movements. Regulate muscle tone.
HOW DOES EXPERIENCE AFFECT BEHAVIOUR AND MENTAL PROCESSES?
Presentation transcript:

III. Parkinson Disease

- Parkinsonism is a clinical syndrome characterized motor disturbances and may be seen in a range of diseases that damage dopaminergic neurons, which project from the substantia nigra to the striatum.

Parkinsonism characterized by: Diminished facial expression (often termed masked facies), Stooped posture, Slowing of voluntary movement, Festinating gait (progressively shortened, accelerated steps), Rigidity, and a “pill-rolling” tremor.

- Causes: Several neurodegenerative diseases , main example is Parkinson disease (PD) 2. Toxins that selectively damage the dopaminergic system

a. MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), causes an an acute parkinsonian syndrome and destruction of neurons in the substantia nigra

b. Pesticide exposure 3. Post encephalitic parkinsonism that followed pandemic influenza in 1918

In the absence of a toxic or other known underlying etiology. - Thee diagnosis of PD can be based on: The presence of triad of parkinsonism—tremor, rigidity, and bradykinesia In the absence of a toxic or other known underlying etiology. 3. . And is confirmed by symptomatic response to L-DOPA replacement therapy

Note - Although the diagnosis of PD is based in large part on the presence of the motor symptoms, there is clear evidence that the disease is not restricted to dopaminergic neurons or to the basal ganglia

There is evidence that PD is a progressive diseases with stages: It begins lower in the brainstem Involves substantia nigra Then involves cerebral cortex leading to cognitive impairment

Pathogenesis. PD is associated with : Protein accumulation and aggregation 2. Mitochondrial abnormalities, 3. and neuronal loss in the substantia nigra and elsewhere in the brain.

Pathogenesis in sporadic cases Postulated theories Oxidative injury may play a role Neuromelanin , a product of dopamine aut oxidation is capable of forming a complex with iron and potentiates generation of free radicals and oxidative injury

2. Missence mutations in the gene encoding α-synuclein causing extra copies of α-synuclein (which is presynaptic neurotransmitter) favors intracellular aggregation and protofibril formation of this protein

and dopamine reacts with it - And this slows the process of protofibrils to fibril conversion and the protofibrils are toxic to the neurons and this may explain dopaminergic selectivity of α-synuclein associated PD

3. Age related reduced proteasome degradation of α-synuclein may result in an increased intracellular accumulation of synuclein protofibrils

Note - While most PD is sporadic, a series of genetic causes have been identified that shed light on its pathogenesis.

1. Autosomal dominant parkinson disease a 1. Autosomal dominant parkinson disease a. Caused by point mutations and amplifications of the region of chromosome 4q21 that contains the gene which encodes α-synuclein, an abundant lipid-binding protein normally associated with synapses.

This protein was then demonstrated to be a major component of the Lewy body, which is the diagnostic hallmark of PD

α-synuclein form small which appear to be toxic to neurons.

b. Mutations in the gene encoding LRRK2 (leucine-rich repeat kinase 2) - Are a more common cause of autosomal dominant PD and are found in some sporadic cases of the disease.

- LRRK2 is a cytoplasmic kinase. - The mutations increase the kinase activity of LRRK2, which leads to hyperphosphorylation of normal targets

2. Autosomal recessive PD - Caused by Mutations in the genes that encode the proteins DJ-1, PINK1, and parkin. a. DJ-1 acts a as a transcriptional regulator, but in settings of oxidative stress it can relocate to the mitochondria and have cytoprotective effects.

- So loss of function mutqion in DJ1 leads to oxidative stress in the mitochondria and damage to neurons by free radicals

b. PINK1 Is a kinase that is degraded in the mitochondria under normal circumstances; And with mitochondrial dysfunction, it recruits parkin, which is an E3 ubiquitin ligase.

Under normal circumstances, the combination of PINK1 and parkin results in clearance of dysfunctional mitochondria through mitophagy

Therefore loss of function mutations in these genes lead to loss of mitophagy of dysfunctional mitochondria So dysfunctional mitochondria will lead to formation of large amounts of free radicals that will damage neurons

Morphology Macroscopic appearance: - A characteristic finding in PD is pallor of the substantia nigra and locus ceruleus, which is due to loss of the pigmented, catecholaminergic neurons in these regions.

Parkinson disease

Microscopic findings Loss of the pigmented, catecholaminergic neurons in these regions associated with gliosis.

2. Lewy bodies May be found in those neurons that remain viable and these are single or multiple, intracytoplasmic, eosinophilic, inclusions that often have a dense core surrounded by a pale halo

Lewy bodies

Immunostains for α-synuclein

Neurochemistry of parkinson disease Loss of cells from substantia nigra pars compacta(SNc) leads to reduced inhibitory dopaminergic input into the striatum This in turn results in increase release of GABA from striatum to lateral globus pallidus

3. Decrease GABA release from lateral globus to Subthalamic nucleus , therefore the subthalamic nucleus production of excitaroy gluatamte increases to the medial globus pallidus and then medial globus pallidus will increase its release of inhibitory GABA to the thalamus

GABA is inhibitory so it will lead to decrease glutamate from thalamic nuclei to the cortex and this leads to akinetic rigid syndrome of parkinson